Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII)

Meir Bialer, Svein I. Johannessen, Harvey J. Kupferberg, René H. Levy, Emilio Perucca, Torbjörn Tomson

Research output: Contribution to journalArticlepeer-review


The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the 9th to 13th May 2004. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included advances in pathophysiology of drug resistance, new AEDs in pediatric epilepsy syndromes, modes of AED action and spectrum of adverse effects and a re-appraisal of comparative responses to AED combinations. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on second-generation AEDs. This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel, ucb 34714 and valrocemide (TV 1901). Updates on felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide, new oral and parenteral formulations of valproic acid and SPM 927 and the antiepileptic vagal stimulator device are also presented.

Original languageEnglish
Pages (from-to)1-48
Number of pages48
JournalEpilepsy Research
Issue number1-3
Publication statusPublished - Sep 2004


  • Antiepileptic drugs
  • Clinical trials
  • Conference
  • Drug development
  • Epilepsy
  • Pharmacology

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology


Dive into the research topics of 'Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII)'. Together they form a unique fingerprint.

Cite this